Active ingredientDiroximel FumarateCat. No. P-D151-001CAS 1577222-14-0Family · Pharmaceutical analytical standards
Diroximel
Diroximel fumarate is an oral fumarate that is rapidly converted in the body into monomethyl fumarate, the active form: approved in the United States in October 2019 and in Europe in 2021 for relapsing forms of multiple sclerosis. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Fumarates in medicine began in Germany: in 1959 the chemist Walter Schweckendiek, who had psoriasis, proposed a link with fumaric acid and tested its esters on himself; they were later approved for psoriasis in 1994.
Go to the active ingredient →Active ingredientDiroximel FumarateCat. No. P-D151-001CAS 1577222-14-0
Isotopically labelledDiroximel Fumarate-d4Cat. No. P-D151-002
ImpurityDiroximel Impurity 1Cat. No. P-D151-003CAS 2101811-42-9
ImpurityDiroximel Fumarate Impurity ACat. No. P-D151-004CAS 2101811-40-7
ImpurityDiroximel Impurity 2Cat. No. P-D151-005CAS 2101811-41-8
ImpurityDiroximel Impurity 3 HydrochlorideCat. No. P-D151-006
ImpurityDiroximel Impurity 4Cat. No. P-D151-007![N-[2-Hydroxyethyl]succinimide](https://img.vitasanlabs.com/vsl-struct/P-D151-008.svg?v=41e934f030)
ImpurityN-[2-Hydroxyethyl]succinimideCat. No. P-D151-008CAS 18190-44-8No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.